Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,473 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Feasibility of methotrexate discontinuation following tocilizumab and methotrexate combination therapy in patients with long-standing and advanced rheumatoid arthritis: a 3-year observational cohort study.
Miyata M, Hirabayashi Y, Munakata Y, Urata Y, Saito K, Okuno H, Yoshida M, Kodera T, Watanabe R, Miyamoto S, Ishii T, Nakazawa S, Takemori H, Ando T, Kanno T, Komagamine M, Kato I, Takahashi Y, Komatsuda A, Endo K, Murai C, Takakubo Y, Miura T, Sato Y, Ichikawa K, Konta T, Chiba N, Muryoi T, Kobayashi H, Fujii H, Sekiguchi Y, Hatakeyama A, Ogura K, Sakuraba H, Asano T, Kanazawa H, Suzuki E, Takasaki S, Asakura K, Suzuki Y, Takagi M, Nakayama T, Watanabe H, Miura K, Mori Y; Michinoku Tocilizumab Study Group. Miyata M, et al. Among authors: kato i. Fukushima J Med Sci. 2023 Apr 5;69(1):11-20. doi: 10.5387/fms.2022-06. Epub 2023 Mar 30. Fukushima J Med Sci. 2023. PMID: 36990790 Free PMC article. Retracted.
Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group.
Hirabayashi Y, Munakata Y, Miyata M, Urata Y, Saito K, Okuno H, Yoshida M, Kodera T, Watanabe R, Miyamoto S, Ishii T, Nakazawa S, Takemori H, Ando T, Kanno T, Komagamine M, Kato I, Takahashi Y, Komatsuda A, Endo K, Murai C, Takakubo Y, Miura T, Sato Y, Ichikawa K, Konta T, Chiba N, Muryoi T, Kobayashi H, Fujii H, Sekiguchi Y, Hatakeyama A, Ogura K, Sakuraba H, Asano T, Kanazawa H, Suzuki E, Takasaki S, Asakura K, Sugisaki K, Suzuki Y, Takagi M, Nakayama T, Watanabe H, Miura K, Mori Y; Michinoku Tocilizumab Study Group. Hirabayashi Y, et al. Among authors: kato i. Mod Rheumatol. 2016 Nov;26(6):828-835. doi: 10.3109/14397595.2016.1160991. Epub 2016 Apr 21. Mod Rheumatol. 2016. PMID: 26934116
Mark4 ablation attenuates pathological phenotypes in a mouse model of tauopathy.
Sultanakhmetov G, Limlingan SJM, Fukuchi A, Tsuda K, Suzuki H, Kato I, Saito T, Weitemier AZ, Ando K. Sultanakhmetov G, et al. Among authors: kato i. Brain Commun. 2024 Apr 17;6(3):fcae136. doi: 10.1093/braincomms/fcae136. eCollection 2024. Brain Commun. 2024. PMID: 38712317 Free PMC article.
Two acute kidney injury episodes after ICI therapy: a case report.
Ishiga K, Kobayashi R, Kanaoka T, Harada J, Kato I, Fujii S, Wakui H, Toya Y, Tamura K. Ishiga K, et al. Among authors: kato i. CEN Case Rep. 2024 Mar 7. doi: 10.1007/s13730-024-00855-5. Online ahead of print. CEN Case Rep. 2024. PMID: 38453804 Free article.
1,473 results